A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

NCT02908100 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: GDC-0853
DRUG: Placebo

Sponsor

Genentech, Inc.